GGrantIndex
← Search

Development of Mutivalent Filovirus (Ebola and Marburg) Vaccines

$9,210,189N01FY2010AINIH

Integrated Biotherapeutics, Inc., Rockville MD

Investigators

Abstract

This contract supports the advanced development of a of multivalent filovirus (Ebola and Marburg) vaccine through cGMP manufacturing with an option for a Phase 1 clinical trial. Additional options provide address Large Scale Production, development of a lyophilized formulation and a Phase 2 Clinical Trial. IBT's product has proven effective in various animal models and is in early preclinical evaluation.

View original record on NIH RePORTER →
Development of Mutivalent Filovirus (Ebola and Marburg) Vaccines · GrantIndex